The findings highlight the importance of future studies on the risk-benefit ratio of antiepileptic
drugs in old adults and especially in those with Alzheimer's disease.
"Antidepressants, such as mirtazapine and amitriptyline, and antiepileptics
, such as gabapentin and pregabalin, can offer significant relief to a good number of patients, though success is variable and as we found in our study, the evidence available is limited," senior author Adam Friedman, MD, professor of dermatology at George Washington University, said in an interview.
On the other hand, herbal medicines are widely used across the globe due to their wide applicability and therapeutic efficacy coupled with least side effects, which in turn has accelerated the scientific research regarding the antiepileptic
Epilepsy has no relation with age, race, socio-geographic or national boundaries.3 Different drugs for the treatment of epilepsy are available but the most common treatment for epilepsy is monotherapy with antiepileptic
drugs (AEDs) and about 50% patients are treated successfully with monotherapy.4 Carbamazepine (CBZ) is used as a first line drug to control different forms of epilepsy.
Parents were asked in detail about risk factors like trauma, medical or surgical history, birth history, type and number of antiepileptics
prescribed, all drugs doseswere calculated according to weight, duration and compliance especially any gaps in treatment, frequency of seizures in last 3 months while on treatment and it was recorded on a performa by the researcher.
The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic
Drugs (MONEAD) study assessed neurodevelopmental outcomes in 311 children whose mothers took valproate, phenytoin, carbamazepine, or lamotrigine for epilepsy during pregnancy.
Adverse reactions to antiepileptic
drugs (AEDs) occur to a certain degree in almost 80% of patients and are a major concern for physicians (1, 2).
* loss of response (therapeutic failure) to antiepileptics
Many women hear about the teratogenic potential of antiepileptics
and decide to stop epilepsy treatment entirely.
The use of antiepileptic
drugs does not appear to raise the risk of suicide beyond the increased risk already associated with the underlying conditions for which patients take these medicines, according to results from a large database analysis.
In the alert, FDA recommended that "all patients treated with antiepileptic
drugs should be monitored for suicidality and other unusual changes in behavior." Providers should "balance the risk for suicidality with the clinical need for the drug." An important finding was the consistency in suicide risk across the studies.
Depakote and Depakene), a leading antiepileptic
drug currently approved for use in the treatment of epilepsy, migraine prophylaxis and bipolar disease, in preclinical studies completed to date, this stereoisomer of valnoctamide has not been associated with the safety concerns (i.e., teratogenicity, and hepatotoxicity) of valproate and its related analogues.